HOXA9 and acute myeloid leukemia: To test the anti-leukemic activity of PLA therapy in primary AML [86], primary cells from AML patients (Fig. 8a and Additional file 1: Figure S5I) as well as two murine AML models driven by Hoxa9/Meis1 or MLL-AF9 (Fig. 8b), were used.